Cite
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]
MLA
Roviello, G., et al. The Prognostic Role of Inflammatory Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: A Translational Study [ASCENT]. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315684413&authtype=sso&custid=ns315887.
APA
Roviello, G., Clarke, S., Burge, M., Feeney, K., Gibbs, P., Jones, K., Marx, G., Molloy, M., Price, T., Reece, W., Segelov, E., & Tebbutt, N. (2020). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Chicago
Roviello, G, Sj Clarke, M Burge, K Feeney, P Gibbs, K Jones, G Marx, et al. 2020. “The Prognostic Role of Inflammatory Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: A Translational Study [ASCENT].” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315684413&authtype=sso&custid=ns315887.